Burney Co. reduce holdings in Johnson & Johnson (NYSE:JNJ)

Burney Co. lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,684 shares of the company’s stock after selling 1,353 shares during the quarter. Burney Co. holdings. in Johnson & Johnson were worth $4,339,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Christopher J. Hasenberg Inc bought a new stake in Johnson & Johnson in the 1st quarter valued at $31,000. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $44,000. Disciplined Equity Management Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $45,000. MFA Wealth Advisors LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $43,000. Finally, Grayhawk Investment Strategies Inc. raised its position in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares in the last quarter. Institutional investors own 69.55% of the company’s shares.

Changes in Analyst Ratings

A number of analysts recently issued reports on JNJ shares. TD Securities cut their price target on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. TD Cowen decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Sanford C. Bernstein upped their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, August 16th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21, according to MarketBeat.com.

Read the latest stock report on JNJ

Johnson & Johnson stocks rose 0.2%

Shares of Johnson & Johnson stock opened at $164.60 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $165.83. The stock has a market cap of $396.14 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07, and a quick ratio of 0.85. The company has a fifty day moving average price of $155.01 and a 200 day moving average price of $153.38.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. In the same period last year, the company earned $2.80 per share. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a dividend of $4.96 on an annualized basis and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Recommended articles

Want to see what other hedge funds JNJ owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Free Report).

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.